fda declaratory order semaglutide shortage resolved feb 21 2025 february The FDA has issued a warning to FDA's Coordinated Enforcement on GLP-1 FDA Announces Resolution of Semaglutide

Cardiovascular outcomes trials demonstrate favourable safety profiles with some agents reducing major adverse cardiovascular events

The rats in the control group were subjected to a sham operation and were later treated with 0.9% NaCl only

Suzuki M, Betsuyaku T, Ito Y, et al

Acknowledgements This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HH21C0004), and a National Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT) (NRF-2020R1F1A1072720)

Nonetheless, the MCKD was not able to rescue tumor growth in vivo to the level of Cpt1a-proficient ErbB2+ tumor cells (Supplementary Fig